selective estrogen receptor degrader AZD9496
Term · Oncology and biomedicine · MLC-T-ONC-016669
An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, SERD AZD9496 binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.
| Identifier | MLC-T-ONC-016669 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | SERD AZD9496 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016669",
"term": "selective estrogen receptor degrader AZD9496",
"field": "Oncology and biomedicine",
"definition": "An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, SERD AZD9496 binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.",
"synonyms": [
"SERD AZD9496"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/selective-estrogen-receptor-degrader-azd9496/"
}
Record 14,801 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.